SCHEDULE: Morgan Stanley Reports 5.6% Stake in Radiopharm Theranostics

Morgan Stanley and its subsidiary, Morgan Stanley Australia Securities Limited, have reported beneficial ownership of 5.6% of Radiopharm Theranostics Ltd's ordinary shares/ADS.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley Australia Securities Limited, have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of 272,558,527 ordinary shares or American Depositary Shares of Radiopharm Theranostics Ltd.
• This ownership represents 5.6% of the class of securities.
• The filing is made as of September 30, 2026, with the report date being November 13, 2026.
• Both entities are registered as brokers or dealers.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without new strategic or financial performance information.

Positives

• Morgan Stanley's reporting of a significant stake (5.6%) can be interpreted as a sign of institutional interest in Radiopharm Theranostics.
• The filing is current and adheres to regulatory requirements, providing transparency to the market.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Radiopharm Theranostics, limiting insight into the company's operational health.
• The ownership is reported as 'shared' voting and dispositive power, indicating a lack of sole control by either reporting entity.

Risks

• The filing does not explicitly mention any risks associated with Radiopharm Theranostics itself, as it is a disclosure of ownership by Morgan Stanley.
• Potential future changes in Morgan Stanley's beneficial ownership could impact Radiopharm Theranostics' share price and investor sentiment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Radiopharm Theranostics Ltd.

Management Comments

• Morgan Stanley and Morgan Stanley Australia Securities Limited jointly agree to file this Schedule 13G on behalf of each party.
• Authorized signatories Claire Gordon (Morgan Stanley) and Brett Graham (Morgan Stanley Australia Securities Limited) certified the accuracy and completeness of the filing.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like Morgan Stanley when their beneficial ownership crosses a certain threshold. This filing indicates a passive investment stake rather than an active control position.

Stakeholder Impact

• Shareholders of Radiopharm Theranostics Ltd are informed of a significant institutional investor's stake, which may influence market perception.
• The filing provides transparency to the market regarding ownership structure.

Next Steps

• Morgan Stanley and its subsidiary will continue to hold the reported shares.
• Future filings will be made if there are changes in beneficial ownership exceeding reporting thresholds.

Key Dates

Keywords

Radiopharm Theranostics, Morgan Stanley, Schedule 13G, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Broker-Dealer